Neoleukin Therapeutics (NLTX) Competitors $21.78 +0.01 (+0.05%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NLTX vs. CRON, SION, MENS, XERS, NUVB, TRVI, DNA, KALV, VIR, and ANABShould you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Cronos Group (CRON), Sionna Therapeutics (SION), Jyong Biotech (MENS), Xeris Biopharma (XERS), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Ginkgo Bioworks (DNA), KalVista Pharmaceuticals (KALV), Vir Biotechnology (VIR), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry. Neoleukin Therapeutics vs. Its Competitors Cronos Group Sionna Therapeutics Jyong Biotech Xeris Biopharma Nuvation Bio Trevi Therapeutics Ginkgo Bioworks KalVista Pharmaceuticals Vir Biotechnology AnaptysBio Neoleukin Therapeutics (NASDAQ:NLTX) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings. Which has stronger earnings & valuation, NLTX or CRON? Cronos Group has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-7.00Cronos Group$117.61M6.39$41.08M$0.1315.00 Does the media favor NLTX or CRON? In the previous week, Cronos Group had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Cronos Group and 0 mentions for Neoleukin Therapeutics. Cronos Group's average media sentiment score of 0.25 beat Neoleukin Therapeutics' score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Cronos Group Neutral Is NLTX or CRON more profitable? Cronos Group has a net margin of 39.69% compared to Neoleukin Therapeutics' net margin of 0.00%. Cronos Group's return on equity of -0.07% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Cronos Group 39.69%-0.07%-0.07% Which has more risk and volatility, NLTX or CRON? Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Do institutionals & insiders believe in NLTX or CRON? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryCronos Group beats Neoleukin Therapeutics on 10 of the 12 factors compared between the two stocks. Get Neoleukin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLTX vs. The Competition Export to ExcelMetricNeoleukin TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$204.69M$786.70M$5.47B$9.53BDividend YieldN/A4.84%4.73%4.09%P/E Ratio-7.001.3728.8923.83Price / SalesN/A25.68371.4466.13Price / CashN/A19.5635.4557.96Price / Book1.976.688.265.54Net Income-$57.56M-$3.67M$3.25B$259.28M7 Day Performance-4.14%-5.23%-3.73%-4.66%1 Month Performance13.50%-0.79%4.28%4.40%1 Year Performance-46.24%15.44%25.85%17.92% Neoleukin Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLTXNeoleukin TherapeuticsN/A$21.78+0.0%N/A-46.3%$204.69MN/A-7.0090Gap DownHigh Trading VolumeCRONCronos Group2.5755 of 5 stars$2.16+3.1%N/A-17.0%$831.14M$117.61M16.58450News CoverageUpcoming EarningsSIONSionna TherapeuticsN/A$18.34+5.2%$38.50+109.9%N/A$809.23MN/A0.0035Positive NewsLockup ExpirationMENSJyong BiotechN/A$10.60-3.6%N/AN/A$805.90MN/A0.0031Positive NewsQuiet Period ExpirationXERSXeris Biopharma3.4832 of 5 stars$5.15+0.1%$6.25+21.5%+121.4%$804.60M$222.55M-17.15290News CoveragePositive NewsUpcoming EarningsShort Interest ↑NUVBNuvation Bio2.2444 of 5 stars$2.36+0.2%$7.17+204.3%-37.4%$801.31M$7.87M-1.0060News CoverageUpcoming EarningsGap UpTRVITrevi Therapeutics2.9347 of 5 stars$6.70-1.7%$20.88+211.4%+136.5%$785.26MN/A-14.8820News CoverageUpcoming EarningsShort Interest ↑DNAGinkgo Bioworks1.1761 of 5 stars$13.15+16.1%$8.50-35.4%N/A$784.60M$227.04M-1.46640News CoverageGap UpKALVKalVista Pharmaceuticals3.8191 of 5 stars$15.66+0.6%$26.29+67.9%-4.5%$781.53MN/A-4.24100VIRVir Biotechnology2.8746 of 5 stars$5.65+2.3%$30.25+435.9%-48.3%$778.98M$74.21M-1.34580News CoverageUpcoming EarningsShort Interest ↑ANABAnaptysBio2.2031 of 5 stars$26.39+0.8%$42.38+60.6%-27.6%$773.43M$111.87M-5.43100News CoverageUpcoming Earnings Related Companies and Tools Related Companies Cronos Group Alternatives Sionna Therapeutics Alternatives Jyong Biotech Alternatives Xeris Biopharma Alternatives Nuvation Bio Alternatives Trevi Therapeutics Alternatives Ginkgo Bioworks Alternatives KalVista Pharmaceuticals Alternatives Vir Biotechnology Alternatives AnaptysBio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NLTX Stock Alerts